用于癌症成像的正电子发射断层显像（PET）放射性药物的开发方法。
Method to Development of PET Radiopharmaceutical for Cancer Imaging.
作者信息
Damuka Naresh, Solingapuram Sai Kiran Kumar
机构信息
Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
出版信息
Methods Mol Biol. 2022;2413:13-22. doi: 10.1007/978-1-0716-1896-7_3.
The increasing number of different novel positron emission tomography (PET) radiopharmaceuticals poses challenges for their manufacturing procedures at different PET research facilities. Recent commercially available radiochemistry units with disposable cassettes are becoming common stations to produce radiopharmaceuticals with high specifications to understand the critical PET imaging outputs of the study. Therefore, several radiochemists across the PET research centers develop and optimize their own radiochemistry protocols to develop a novel or routine radiopharmaceutical at their lab. In this report, we describe the general procedure and steps followed to develop a (clinical-grade) radiopharmaceutical on a commercially available radiochemistry unit, TRASIS AIO. As an example, we use our routine protocol followed for the production of [C]acetate, a fatty acid metabolic PET imaging ligand for several cancer imaging studies.
新型正电子发射断层扫描（PET）放射性药物种类日益增多，这给不同PET研究机构的生产流程带来了挑战。近期市面上出现的带有一次性盒式装置的放射化学单元正逐渐成为生产高规格放射性药物的常用设备，以明确研究中关键的PET成像结果。因此，PET研究中心的几位放射化学家会开发并优化自己的放射化学方案，以便在其实验室中研发新型或常规放射性药物。在本报告中，我们描述了在市售放射化学单元TRASIS AIO上开发（临床级）放射性药物所遵循的一般程序和步骤。例如，我们使用常规方案来生产[C]醋酸盐，这是一种用于多项癌症成像研究的脂肪酸代谢PET成像配体。
Zotero 插件